Key Dates

Related Announcements

NOT-HL-21-015 - Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence and Adolescence to Young Adulthood

PAR-21-119 - NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required)

PAR-21-118 - NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R33 Clinical Trial Required)

PAR-19-329 - Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials

PAR-19-330 - Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)

PAR-19-328 - Single-Site Investigator-Initiated Clinical Trial

PAR-21-079 - NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The National Heart, Lung, and Blood Institute (NHLBI) is issuing this Notice to highlight its interest in research to promote cardiovascular and cardiometabolic health in early stages of the lifecourse: Pre-adolescence and Adolescence to Young Adulthood. Such research interests include but are not limited to: transitionary phases across the lifecourse, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years). NHLBI encourages the submission of applications unique to:

1) understanding the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitionary phases from pre-adolescence into adolescence and adolescence into young adulthood, and 2) developing precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitionary phases.

Examples of research include but are not limited to:

• Test the efficacy of evidence‐based strategies that improve biomarkers of cardiometabolic health and promote healthy lifestyle behaviors in adolescents and young adults, especially those who experience health disparities
• Interventions that test the utility of cutting‐edge digital approaches into all aspects of study design, including leveraging innovative assessment methods that easily integrate patient self‐entry of data, transmit home BP measurements, and automatically capture dense digital data from wearable devices
• Interventions that utilize population management tools to capitalize on the wealth of information available from electronic health records, with an emphasis on recruitment of high‐risk young adults
• Interventions targeting primordial and primary prevention that test the efficacy of the AHA health behaviors of the Simple 7 indicators (tobacco or e-cigarettes use or exposure, obesity, dietary intake, and physical activity), sedentary behavior and sleep habits—with the goal of lowering the prevalence of cardiovascular risk factors among the young adult population
• Interventions that test the efficacy of preventative care in adolescents and young adults with co-morbid conditions (e.g., hypertension and obesity; obesity, diabetes and hypertension) to lower cardiovascular disease risk and pre-existing comorbidities
• Efficacy trials targeting adolescents and young adults with comorbid conditions, multiple risk behaviors or psychosocial stressors, such as exposure to childhood adversity or living in adverse SDoH environments
• Efficacy trials to promote resilience skills for promoting health behavioral changes, managing psychosocial stressors, and other factors that are associated with adverse cardiovascular and cardiometabolic health
• Studies that use polygenic risk scores and other indicators of risk (e.g., SDOH factors, physical inactivity, diet, etc.) to harness the data for clinical trials
• Efficacy trials that utilize targeted, precision prevention approaches to address CVD risk among the adolescent and young adult populations

Interested applicants can submit applications to NHLBI's suite of available Clinical Trial Funding Opportunity Announcements located at: https://www.nhlbi.nih.gov/grants-and-training/clinical-trial-development-continuum. 

Applicants are strongly encouraged to discuss potential applications with one of the NHLBI Scientific/Research Contacts listed below prior to submission. NHLBI also strongly suggests that applicants responding to this Notice (NOT-HL-21-020) indicate so in their cover letter.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Alison G.M. Brown, PhD, MS, RDN
National Heart Lung and Blood Institute (NHLBI)
National Institutes of Health
Telephone: 301-435-0583
Email: Alison.brown@nih.gov

Laurie Donze, PhD
National Heart Lung and Blood Institute (NHLBI)
National Institutes of Health
Telephone: 301-827-1408
Email: laurie.donze@nih.gov